Wall Street brokerages expect Myomo, Inc. (NASDAQ:MYO) to announce ($0.17) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Myomo’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.17). Myomo reported earnings of ($0.22) per share during the same quarter last year, which would indicate a positive year over year growth rate of 22.7%. The firm is expected to announce its next quarterly earnings report on Thursday, March 5th.
According to Zacks, analysts expect that Myomo will report full-year earnings of ($0.67) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.64). For the next year, analysts expect that the firm will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.67) to ($0.25). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Myomo.
Myomo (NASDAQ:MYO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $1.30 million.
Separately, Roth Capital cut Myomo from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.
MYO stock remained flat at $$0.49 during mid-day trading on Tuesday. The company’s stock had a trading volume of 30,747 shares, compared to its average volume of 130,863. Myomo has a 1-year low of $0.43 and a 1-year high of $1.87. The company has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $0.72.
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Featured Article: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.